GleamWall
中文EN

QCLS Q/C TECHNOLOGIES, INC.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1321834 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-120.7%
TTM EPS YoY105.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-113.0%
ROA-58.8%
ROIC (approx.)-131.5%
Asset turnover—

Leverage & solvency

Liabilities / assets10.2%
Debt / equity0.00x
Current ratio5.06x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-25.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$383,382$236,133$510,534$696,504$356,352$873,472$1.55M$1.13M
SG&A expense$1.10M$1.00M$1.07M$1.03M$967,833$894,297$841,685$969,145
Operating income-$2.57M-$7.76M-$3.40M-$3.71M-$1.79M-$1.87M-$2.47M-$2.19M
Pretax income-$941,793-$6.62M-$1.24M-$5.89M-$2.81M-$1.80M-$1.12M-$2.06M
Net income-$941,793-$7.59M-$2.79M-$5.89M-$2.81M-$1.80M-$1.12M-$2.06M
EBITDA-$2.55M-$7.76M——-$1.79M-$1.87M——
EPS (basic)-0.14-0.91-0.38—-2.50-51.10-0.36—
EPS (diluted)-0.14-0.91-0.38—-2.50-51.10-0.36—
Weighted avg. shares (diluted)8.52M8.24M8.06M—1.48M54,2615.35M—
Balance sheet
Cash & equivalents$2.59M$307,612$1.13M$986,996$6.90M$207,553$73,244$173,154
Short-term investments$6.81M$10.68M$11.85M$14.80M$3.09M$3.61M$5.81M$8.35M
Current assets$10.20M$11.74M$13.71M$16.58M$11.15M$5.15M$6.78M$9.41M
PP&E, net$145,258$140,868——————
Goodwill$10.50M$10.50M$10.50M$10.50M$10.50M$10.50M$10.50M$10.50M
Intangibles——$14.09M$14.09M————
Total assets$21.28M$22.87M$38.29M$41.17M$37.23M$17.15M$18.78M$21.42M
Current liabilities$2.02M$3.57M$3.69M$5.53M$6.53M$5.55M$4.94M$6.70M
Total liabilities$2.18M$3.79M$14.60M$16.44M$15.91M$5.55M$4.94M$6.70M
Shareholders' equity$16.12M$16.09M$20.72M$21.75M$14.32M$5.28M$8.69M$9.79M
Shares outstanding8.50M8.19M7.85M7.69M2.98M29.38M7.39M33,636
Cash flow statement
Operating cash flow-$1.54M-$1.82M-$3.29M-$3.20M-$1.16M-$2.07M-$2.64M-$764,115
Capital expenditure$17,103———————
Free cash flow-$1.55M———————
Investing cash flow$3.87M$1.04M$2.97M-$11.67M-$1.49M$2.20M$2.54M$1.10M
Financing cash flow-$55,995-$42,896$453,930$8.95M———-$1.36M
Depreciation & amortization$12,713$5,341——$0$0——
Stock-based compensation$860,667$3.34M$1.60M$1.99M$0$104,854$84,636$83,344

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.